US EditionPublished • loading... • Updated
Wegovy-Maker Novo Nordisk Warns Price Cuts 'Painful' for Firm as Shares Plunge
Novo Nordisk expects up to a 13% sales drop in 2026 due to US price cuts on GLP-1 drugs, causing an 18% share plunge on the Copenhagen exchange.
- On Wednesday, Novo Nordisk shares plunged 18% to around 302 kroner on the Copenhagen stock exchange, erasing nearly $32 billion of market value since Tuesday.
- Novo Nordisk said on Tuesday its guidance assumes lower realised prices from market-access investments amplified by a most favoured nation agreement with the US Administration, while rivalry among GLP-1 makers and US pressure lowered costs.
- Doustdar said that the share price 'goes down before it comes back up' and warned sales and profit will fall 5-13% this year, amid unprecedented pricing pressures.
- Users on the TrumpRx site would pay Wegovy and Zepbound from $350 per month, dropping to $250, while Medicare prices are set at $245, according to analysts' claims.
- Despite an FDA approval in December, Novo Nordisk reported 2025 sales rose six percent to 309 billion kroner, below the November forecast of eight to 11 percent growth.
Insights by Ground AI
Podcasts & Opinions
32 Articles
32 Articles
Jyllands-PostenReposted by 
avisendanmark.dk
avisendanmark.dkDanish pharmaceutical giant Novo Nordisk's expectations for this year have apparently not gone down well with investors. As of late Wednesday afternoon at the stock exchange close, the pharmaceutical company's B-share is...
·Aarhus, Denmark
Read Full Article
Here is the reason for the Novo Nordisk share plunge explained in one graphic.
·Copenhagen, Denmark
Read Full ArticleCoverage Details
Total News Sources32
Leaning Left7Leaning Right3Center6Last UpdatedBias Distribution44% Left
Bias Distribution
- 44% of the sources lean Left
44% Left
L 44%
C 37%
R 19%
Factuality
To view factuality data please Upgrade to Premium
